Stress, high blood pressure, smoking, pollution, fast foods, overweight, excessive travelling, surgery, less movement are common features in our modern life. These features are risky for blood clotting disorders. According to WHO, over 29% of the total mortalities worldwide are due to thrombosis. By the year, 2020 cardiovascular diseases (CVDs) may cause an estimated 25 million deaths per year, thus antithrombotic therapy is of great interest. The available thrombolytic agents such as urokinase are highly expensive, antigenic, quite unspecific, pyretogenic and hemorrhagenic. Therefore, the production of fibrinolysing enzymes, which rapidly dissolute thrombi within the vascular tree, without the detriments by microorganisms, as described in this book, is the desirable aim of today’s research. Integrated practical and theoretical trends. Describes fibrinolytic microbial enzymes for clinical applications. Provides an outlook to future research.
- ISBN: 978-3-642-24979-2
- Editorial: Springer Berlin Heidelberg
- Encuadernacion: Rústica
- Páginas: 101
- Fecha Publicación: 31/12/2011
- Nº Volúmenes: 1
- Idioma: Inglés